These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 10080588)

  • 1. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.
    Tolcher AW; Sugarman S; Gelmon KA; Cohen R; Saleh M; Isaacs C; Young L; Healey D; Onetto N; Slichenmyer W
    J Clin Oncol; 1999 Feb; 17(2):478-84. PubMed ID: 10080588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
    Saleh MN; Sugarman S; Murray J; Ostroff JB; Healey D; Jones D; Daniel CR; LeBherz D; Brewer H; Onetto N; LoBuglio AF
    J Clin Oncol; 2000 Jun; 18(11):2282-92. PubMed ID: 10829049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma.
    Ajani JA; Kelsen DP; Haller D; Hargraves K; Healey D
    Cancer J; 2000; 6(2):78-81. PubMed ID: 11069223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
    Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
    Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.
    Trail PA; Willner D; Bianchi AB; Henderson AJ; TrailSmith MD; Girit E; Lasch S; Hellström I; Hellström KE
    Clin Cancer Res; 1999 Nov; 5(11):3632-8. PubMed ID: 10589780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
    Trail PA; Willner D; Lasch SJ; Henderson AJ; Hofstead S; Casazza AM; Firestone RA; Hellström I; Hellström KE
    Science; 1993 Jul; 261(5118):212-5. PubMed ID: 8327892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology evaluation: SGN-15, Seattle Genetics Inc.
    Smith S
    Curr Opin Mol Ther; 2001 Jun; 3(3):295-302. PubMed ID: 11497354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BR96-doxorubicin: been there, done that!
    Tolcher AW
    J Clin Oncol; 2000 Dec; 18(23):4000. PubMed ID: 11099337
    [No Abstract]   [Full Text] [Related]  

  • 10. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
    Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
    J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
    Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.
    Remsen LG; Trail PA; Hellström I; Hellström KE; Neuwelt EA
    Neurosurgery; 2000 Mar; 46(3):704-9. PubMed ID: 10719867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
    Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and activities of the BR96-doxorubicin immunoconjugate.
    Hellström I; Hellström KE; Senter PD
    Methods Mol Biol; 2001; 166():3-16. PubMed ID: 11217374
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.
    Khoo K; Brandes L; Reyno L; Arnold A; Dent S; Vandenberg T; Lebwohl D; Fisher B; Eisenhauer E
    J Clin Oncol; 1999 Nov; 17(11):3431-7. PubMed ID: 10550138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
    Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
    Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.
    Rivera E; Valero V; Esteva FJ; Syrewicz L; Cristofanilli M; Rahman Z; Booser DJ; Hortobagyi GN
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):299-302. PubMed ID: 11914909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
    Posey JA; Khazaeli MB; Bookman MA; Nowrouzi A; Grizzle WE; Thornton J; Carey DE; Lorenz JM; Sing AP; Siegall CB; LoBuglio AF; Saleh MN
    Clin Cancer Res; 2002 Oct; 8(10):3092-9. PubMed ID: 12374676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.